Brief: Chemomab Reports On Two Scientific Presentations That Support The Potential Therapeutic Utility Of CM-101 In Systemic Sclerosis

Chemomab Therapeutics

14/03/2022 12:19

March 14 (Reuters) - Chemomab Therapeutics Ltd  CMMB.O :
    * CHEMOMAB REPORTS ON TWO SCIENTIFIC PRESENTATIONS THAT
SUPPORT
THE POTENTIAL THERAPEUTIC UTILITY OF CM-101 IN SYSTEMIC
SCLEROSIS
    * CHEMOMAB THERAPEUTICS - CM-101 IS EXPECTED TO BEGIN A
PHASE 2
TRIAL IN SYSTEMIC SCLEROSIS LATER THIS YEAR

Source text for Eikon:  ID:nPn5P27CYa 
Further company coverage:  CMMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))